Most organizations navigating transformation, a technology decision, or a growth inflection point do not lack opinions, from management consultants or technology innovators. What they lack is a partner who has been close enough to the problem, across pharma, biotech, and MedTech, in the commercial and operating functions being transformed, at their level, to help them define what actually matters and what does not.

That is what Audoban brings. Industry executives who have run businesses and functional organizations, managed the P&L through transitions, and made the commercial excellence, market access, and operational calls your leadership team is wrestling with today. People who understand that the technology-driven transformation conversation, spanning AI and data infrastructure, native versus augmentation decisions, operating model design, and platform choices, is only useful when it starts with the actual business problem, not the other way around. And who recognize that most transformations do not fail because the strategy was wrong. They fall short because the noise in the system is too loud, technology advances too fast, and no one is connecting the dots clearly enough to keep the organization focused on what actually moves things forward.

We engage as a thinking partner first. Then we stay to ensure the plan gets delivered, through executive interim leadership, PE and VC investor support, commercial excellence programs, team coaching, or senior program oversight. The format adapts to what each situation requires. The commitment to moving things forward does not.